With crossover round in its pock­et, syn­thet­ic lethal­i­ty-fo­cused Cyteir Ther­a­peu­tics eyes a jump on­to Nas­daq

Cyteir Ther­a­peu­tics CEO Markus Ren­schler has his eye on the mar­ket. The Cel­gene vet pulled in an $80 mil­lion crossover round on Thurs­day to fu­el Cyteir’s lead syn­thet­ic lethal­i­ty pro­gram, and when the time is right, he’ll have the S-1 ready.

“We’re con­sid­er­ing an IPO in 2021,” Ren­schler said, adding that the tim­ing isn’t set in stone.

Un­til then, the Se­ries C should give Cyteir the flex­i­bil­i­ty to grow its team, and ad­vance its lead can­di­date — an in­hibitor of RAD51-me­di­at­ed DNA re­pair dubbed CYT-0851 — to Phase II as a monother­a­py. The small biotech is al­so plan­ning com­bi­na­tion tri­als that pair CYT-0851 with oth­er can­cer treat­ments, like chemother­a­pies and po­ten­tial­ly PARP in­hibitors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER